MPLT

Rating neutralAI Memo

MapLight Therapeutics

As of 2026-07-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ZEPHYR Phase 2 success in schizophrenia • 2026-07-27

Base target: $13 / p=45% prob

Biggest risk

The QD regimen missed its primary endpoint, ZEPHYR still requires replication and regulatory alignment, and IRIS failed its primary endpoint. Low coverage and binary clinical risk limit conviction.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

ZEPHYR provides meaningful clinical validation for the BID regimen, including PANSS, cognition, and tolerability signals, while VISTA and a confirmatory schizophrenia study preserve substantial optionality.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-28

Base target

$13

p=45%

Bull target

$24

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

IRIS primary-endpoint miss limits ASD optionality
VISTA Phase 2 readout in Alzheimer’s disease psychosis
ZEPHYR provides meaningful clinical validation for the BID regimen, including PANSS, cognition, and tolerability signals, while VISTA and a confirmatory schizophrenia study preserve substantial optionality.

BearKey bullets

Clinical, regulatory, execution, and future dilution risks remain material despite reported funding through 2027.
Coverage is low and post-readout analyst revisions or target changes are unavailable.
IRIS missed its primary endpoint, leaving the ASD opportunity dependent on exploratory subgroup evidence.

WatchKey bullets

ZEPHYR Phase 2 success in schizophrenia

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $13 (p=45%)

Target spread vs base: +85% / -62%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $13 (p=45%)Bear Target: $5 (p=30%)

Commentary

Primary-source sentiment improved materially after the positive ZEPHYR BID result, but the QD miss, prior IRIS failure, reported sharp selloff, absent social context, and unavailable analyst revisions support a cautious monitoring stance rather than a high-conviction bullish view.

As of 2026-07-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

The QD regimen missed its primary endpoint, ZEPHYR still requires replication and regulatory alignment, and IRIS failed its primary endpoint. Low coverage and binary clinical risk limit conviction.

Drivers

Scannable catalysts and supporting factors

IRIS primary-endpoint miss limits ASD optionality
VISTA Phase 2 readout in Alzheimer’s disease psychosis

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$13 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-07-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-27
ZEPHYR Phase 2 success in schizophrenia
The 210/3 mg BID arm met the primary PANSS endpoint with effect size 0.37 and showed positive cognition and secondary-endpoint results; the QD arm did not reach statistical significance [#SEC-8K-2026-07-27].
Prob 100.00% • Move 20.00% • Priced-in 75.00%
EVENT2026-10-26
FDA interaction and confirmatory-trial planning
MapLight plans an End-of-Phase 2 FDA meeting and an additional registrational trial for ML-007C-MA, but the regulatory path and replication remain uncertain [#SEC-8K-2026-07-27].
Prob 60.00% • Move 25.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

IRIS primary-endpoint miss limits ASD optionality
2026-06-22
The IRIS Phase 2 study missed its primary endpoint; a promising adolescent irritability subgroup supports further FDA discussion but remains exploratory [#PR-EARNINGS-2026-06-22].
Prob 85% • Move -10% • Priced-in 85%

Long-term Catalysts

Months to a year

VISTA Phase 2 readout in Alzheimer’s disease psychosis
2027-07-28
The ongoing VISTA trial evaluates ML-007C-MA at the BID dose, with topline results expected in the second half of 2027 [#SEC-8K-2026-07-27].
Prob 60% • Move 30% • Priced-in 15%

Risks

Clinical, regulatory, execution, and future dilution risks remain material despite reported funding through 2027.
Coverage is low and post-readout analyst revisions or target changes are unavailable.
IRIS missed its primary endpoint, leaving the ASD opportunity dependent on exploratory subgroup evidence.
The once-daily 330/6 mg regimen failed to achieve statistical significance on the primary endpoint.
ZEPHYR requires an additional confirmatory trial and FDA agreement before a registrational path is established.

Peers

Symbol	Summary
EVMN	Similar small-cap sector-screen candidate, but its asset and indication mix is different; operating read-through is limited.
OCGN	Same-sector, similar-market-cap biotechnology candidate, but not a tight schizophrenia or CNS comparator.
TENX	Small-cap therapeutics peer by sector and size; program differences make company-specific clinical data more important than peer valuation.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-28

Loading AI feed…

Symbol

Summary

EVMN

Similar small-cap sector-screen candidate, but its asset and indication mix is different; operating read-through is limited.

OCGN

Same-sector, similar-market-cap biotechnology candidate, but not a tight schizophrenia or CNS comparator.

TENX

Small-cap therapeutics peer by sector and size; program differences make company-specific clinical data more important than peer valuation.